---
title: Aggressive Squamous Cell Carcinoma in Organ Transplant Recipients
nct_id: NCT02095912
overall_status: COMPLETED
sponsor: University of Zurich
study_type: OBSERVATIONAL
primary_condition: Squamous Cell Carcinoma
countries: Switzerland
canonical_url: "https://parkinsonspathways.com/agent/trials/NCT02095912.md"
clinicaltrials_gov: "https://clinicaltrials.gov/study/NCT02095912"
ct_last_update_post_date: 2016-08-10
last_seen_at: "2026-05-12T06:29:40.685Z"
source: ClinicalTrials.gov (mirrored, no enrichment)
---
# Aggressive Squamous Cell Carcinoma in Organ Transplant Recipients

**NCT ID:** [NCT02095912](https://clinicaltrials.gov/study/NCT02095912)

## Key Facts

- **Status:** COMPLETED
- **Study Type:** OBSERVATIONAL
- **Target Enrollment:** 150
- **Lead Sponsor:** University of Zurich
- **Conditions:** Squamous Cell Carcinoma
- **Start Date:** 2014-03
- **Completion Date:** 2016-01
- **CT.gov Last Update:** 2016-08-10

## Brief Summary

To identify risk factors for aggressiveness in Squamous Cell Carcinoma of the skin in organ transplant recipients.

## Detailed Description

Squamous Cell Carcinomas (SCC) are one of the most common skin cancers. They belong to the epithelial neoplasm of the skin, which manifest a local aggressive growth and have potential for metastasis. Organ transplant recipients have a hundredfold higher incidence of SCC.

Unfortunately the primary tumor, regional nodes, metastasis (TNM)-Classification for the prognosis of SCC in this group of patient has not yet been established. Therefore there are no standardised criteria for evaluation of local recurrence or prognosis.

The aim of this study is to identify criteria, which permit a risk assessment relating to aggressiveness of SCC.

## Eligibility

- **Sex:** ALL
- **Healthy Volunteers:** No

```
Inclusion Criteria:

Organ transplant recipients with:

* \> 9 SCC in total or
* \> 2 SCC per year (in any one year) or
* any single "index" SCC that has a very poorly differentiated cell morphology or that behaved aggressively in Terms of local recurrence or local/systemic metastasis

Exclusion Criteria:

* Non organ transplant recipients
```

## Primary Outcomes

- **Diameter of Squamous Cell Carcinoma** _(time frame: 1 year)_ — * Location
* exact size in mm
* histological classification (well-differentiated, moderately-differentiated, poorly differentiated, spindle cell morphology, desmoplastic, basi-squamous, acantholytic)
* Invasion
* rapid growth
* local recurrence
* sentinel node sampling
* Metastasis

## Secondary Outcomes

- **Sun exposure history** _(time frame: 1 year)_

## Locations (1)

- Universitätsspital Zürich, Zurich, Canton of Zurich, Switzerland

## Recent Field Changes (last 30 days)

- `sponsor.lead` — added _(2026-05-12)_
- `results.hasResults` — added _(2026-05-12)_
- `status.overallStatus` — added _(2026-05-12)_
- `status.primaryCompletionDate` — added _(2026-05-12)_
- `status.completionDate` — added _(2026-05-12)_
- `status.lastUpdatePostDate` — added _(2026-05-12)_
- `design.enrollmentCount` — added _(2026-05-12)_
- `eligibility.criteria` — added _(2026-05-12)_
- `eligibility.sex` — added _(2026-05-12)_
- `outcomes.primary` — added _(2026-05-12)_
- `outcomes.secondary` — added _(2026-05-12)_
- `locations.universitätsspital zürich|zurich|canton of zurich|switzerland` — added _(2026-05-12)_

---

*Canonical: https://parkinsonspathways.com/agent/trials/NCT02095912.md*  
*Source data (authoritative): https://clinicaltrials.gov/study/NCT02095912*  
*This page is a raw mirror with no AI summary, no editorial enrichment, and no Parkinson's-specific filtering.*